Anti-CD47 antibody inhibits hematogenous dissemination of primary human NHL. (A) NSG mice were transplanted subcutaneously with bulk cells from a primary human DLBCL patient (NHL7, supplemental Table 1). Mice with a palpable mass (3 weeks after transplantation) were treated with daily injections of control IgG or anti-CD47 antibody for 11 days. Anti-CD47 antibody treatment had no effect on decreasing tumor volume compared with control IgG (P = .49, 2-way ANOVA). Data are mean ± SD. The presence of human CD45⁺CD19⁺ lymphoma cells in the bone marrow (B-C) and peripheral blood (D) of these mice after treatment (treatment day 11, posttransplantation day 32) was analyzed by flow cytometry. (C-D) Statistical analysis was calculated by Fisher exact test measuring engraftment versus no engraftment. ***P < .0005.